In this Issue:
Risk factors for fibrosis progression in HCV
Severe portal hypertension: risk factor for hepatic decompensation
Target CLDN1 for inhibiting cellular entry of HCV?
Simeprevir + sofosbuvir ± RBV in HCV GT1 with liver cirrhosis
New therapeutic options for entecavir-resistant HBV
Ombitasvir, paritaprevir and ritonavir in HCV GT1b
Ombitasvir, paritaprevir and ritonavir in Japanese patients with HCV GT1b
Inflammatory cytokines/chemokines predict treatment responses?
Antenatal screening for HCV infection cost-effective
Soraphen A shows promising anti-HCV activity
Please login below to download this issue (PDF)